Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study
Aly A Yousef,Faisal Y Mohamed,Naglaa F Boraey,Nagwa E Akeel,Attia A Soliman,Nevin M Waked,Mustafa I A Hashem,Hassan Shehata,Dalia S Fahmy,Ali Ismael,Lamya M Ibrahim,Mohamed A M Ibrahim,Hanan F Salem,Sherif M Yousry,Sherif F Osman,Rania A Fouad,Eman T Enan,Mohammed A Attia,Mona R Afify,Nancy M S Zeidan,Mohamed Nashat,Mustafa IA Hashem,Mohamed AM Ibrahim,Nancy MS Zeidan
DOI: https://doi.org/10.2147/JIR.S277373
IF: 4.5
2020-12-14
Journal of Inflammation Research
Abstract:Aly A Yousef, 1 Faisal Y Mohamed, 2 Naglaa F Boraey, 3 Nagwa E Akeel, 4 Attia A Soliman, 4 Nevin M Waked, 5 Mustafa IA Hashem, 4 Hassan Shehata, 4 Dalia S Fahmy, 6 Ali Ismael, 7 Lamya M Ibrahim, 8 Mohamed AM Ibrahim, 9 Hanan F Salem, 10 Sherif M Yousry, 11 Sherif F Osman, 12 Rania A Fouad, 13, 14 Eman T Enan, 15, 16 Mohammed A Attia, 17, 18 Mona R Afify, 19 Nancy MS Zeidan, 20 Mohamed Nashat 21 1 Department of Pediatrics, Faculty of Medicine, Helwan University, Helwan, Egypt; 2 Department of Pediatrics, Faculty of Medicine, Ain-Shams University, Cairo, Egypt; 3 Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt; 4 Department of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 5 Department of Pediatrics, Faculty of Medicine, October 6 University, October 6, Egypt; 6 Department of Rheumatology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 7 Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 8 Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; 9 Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt; 10 Department of Anesthesia, Faculty of Medicine, Banha University, Banha, Egypt; 11 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt; 12 Department of Radiology, Texas Tech University Health Sciences Center, El Paso, TX, USA; 13 Department of Medical Biochemistry, College of Medicine, El-Mareefa University, Riyadh, Kingdom of Saudi Arabia; 14 Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 15 Department of Pathology, College of Medicine, El-Mareefa University, Riyadh, Kingdom of Saudi Arabia; 16 Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt; 17 Department of Clinical Pharmacology, College of Medicine, El-Mareefa University, Riyadh, Kingdom of Saudi Arabia; 18 Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt; 19 Department of Medical microbiology and Parasitology, Faculty of Medicine, University of Jeddah, Jeddah, 21589, Saudia Arabia; 20 Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt; 21 Department of Pediatrics, Faculty of Medicine, Aswan University, Aswan, Egypt Correspondence: Faisal Y Mohamed Faculty of Medicine, Ain-Shams University, Cairo, Egypt Tel +201113363638 Email Faisalyousef69@gmail.com Background: Plasminogen activator inhibitor-1 (PAI-1) is a key molecule residing at the nexus between thrombosis and inflammatory processes. Recently, PAI-1 and its gene expression have emerged as a potential candidate for autoimmune disorders such as SLE. Objective: To investigate whether the PAI-1 4G/5G polymorphism at position − 675 could be a genetic marker for susceptibility to childhood-onset SLE and development of lupus nephritis among Egyptian children and adolescents. Methods: Three hundred fifty patients diagnosed with childhood-onset SLE and 350 well-matched healthy controls were included in this multi-center study. All subjects were genotyped for the PAI-1 promoter 4G/5G polymorphism at position − 675 using PCR– restriction fragment length polymorphism (RFLP). Serum PAI-1 levels were measured by ELISA. Results: The PAI-1 (- 675) 4G/4G genotype was more represented in c-SLE patients, as compared to the control group (38% vs 23%; OR =2.7; [95% CI: 1.47– 2.9]; P < 0.001). Patients carrying the PAI-1 4G/4G genotype or 4G allele were more likely to develop lupus nephritis (OR: 3.38; [95% CI: 1.9– 5.9]; P < 0.001, for the 4G/4G genotype and OR: 2.6; [95% CI: 1.85– 3.67]; for the 4G allele; P < 0.01). The PAI-1 4G/4G genotype was associated with higher PAI-1 serum concentrations (mean; 86.6± 22.7 ng/mL) as compared to those with a 4G/5G genotype (mean; 48.3± 16.5 ng/mL) and the lowest for the 5G/5G genotype (mean; 34.7± 11.4 ng/mL); P = 0.004. Conclusion: The PAI-1 4G/5G polymorphism may confer susceptibility to childhood-onset SLE and development of lupus nephritis among Egyptian children and adolescents. Moreover, the PAI-1 4G/4G genotype and 4G allele were associated with higher PAI-1 serum levels and higher disease activity scores. Keywords:</str -Abstract Truncated-
immunology